Indian Kanoon - Search engine for Indian Law

India due to the threat of compulsory licensing and development of biosimilar Trastuzumab. The Roche Group also launched another low cost version of Trastuzumab under ... vial. 9. IP-1 initiated the development of a biosimilar drug for Trastuzumab, in joint collaboration with IP-2, in the year 2008. Manufacturing license

2010 & IT(IT)A.884/B/2013 Page - 7 Biosimilars manufactured in India after undergoing clinical trials, failed to appreciate that the agreement contemplates ... express recombinant proteins would be utilised by the appellant to produce the biosimilars for therapeutic use. The cell lines will undergo characterisation and process development